Abstract. Cytokeratin 19 (CK19) is one of the most frequently studied immunohistochemical markers in thyroid pathology. The results of several studies suggest that CK19 may be useful in the diagnosis of papillary carcinoma, where it has been shown to have strong diffuse cytoplasmic reactivity. However, the published results vary, and the utility of CK19 in the diagnosis of thyroid lesions is controversial. The aim of this study was to evaluate, by Western blot analysis and the enzyme-linked immunosorbent assay (ELISA), the expression of CK19 in the cytosolic fraction obtained from 125 specimens of various thyroid lesions: nodular goiters, follicular adenomas, papillary carcinomas, follicular carcinomas and anaplastic carcinomas. The analysis of CK19 expression using the ELISA showed that the majority of papillary carcinoma cases had a much higher level of CK19 than did nodular goiters and adenomas (P<0.001). Western blot analysis revealed the presence of CK19 in 66% of papillary carcinoma cases. CK19 expression was also found in 11, 22, 25 and 25% of nodular goiters, follicular adenomas, and follicular and anaplastic carcinomas, respectively. The results demonstrate that the evaluation of CK19 expression may be helpful in distinguishing papillary carcinoma from other benign and malignant thyroid nodules, but cannot by itself be used to establish a diagnosis.
Introduction
Cytokeratins (CKs) are among the major structural proteins of the epithelial cells, occurring as a cytoplasmic network of 10-to 12-nm-wide intermediate filaments. The primary function of CKs is to protect the epithelial cells from mechanical and non-mechanical stresses (1) . However, recent data suggest they serve other functions as well, for example in cell signaling, stress response and apoptosis (2) (3) (4) (5) (6) . The expression profile of CKs depends on epithelial type and may be altered during carcinogenesis. Neoplastic epithelia may preserve the original CKs of their normal progenitor cells, or may develop various new types (7) . CKs play an important role in the regulation of tumor cell migration and invasion. Chu et al (8) demonstrated that mouse L cells transfected with the human CKs 8 and 18 had higher migratory and invasive abilities than parental and control-transfected cells. Direct evidence has been provided which indicates that the overexpression of CK19 in hepatocellular carcinoma cells is related to their metastatic behavior (9) .
Cytokeratin 19 (CK19), a low molecular weight keratin (40 kDa), is one of the most frequently studied markers in thyroid pathology. CK19 is expressed differentially in various types of thyroid lesions. Although CK19 expression is not specific to malignancy, malignant transformation is usually accompanied by an increased level of CK19 expression. The results of several immunohistochemical and immunocytochemical studies have shown that CK19 may be useful, especially in the diagnosis of papillary carcinoma (10) (11) (12) (13) (14) (15) . Some authors claim that the strong and diffuse reactivity of CK19 in papillary carcinoma can be helpful in differential diagnosis, distinguishing it from other benign and malignant lesions. Nonetheless, the utility of CK19 in the diagnosis of papillary thyroid carcinomas is still in question. In some studies, the positive reaction of CK19 was also found in a large number of follicular carcinomas, follicular adenomas, nodular goiters and even normal tissues (7, (16) (17) (18) . However, it should be stressed that CK19 is typically only focally present in goiters and adenomas, while its expression in papillary carcinomas is strong and uniform. On the other hand, the finding that 50% or more of follicular carcinoma specimens are also CK19 positive suggests that CK19 reactivity is not absolutely reliable in differentiating papillary and follicular carcinoma (7, 12, 17, 19, 20) .
The aim of this study was to evaluate the expression of CK19 in the cytosolic fraction of benign and malignant thyroid lesions using immunological methods, namely Western blot analysis and the enzyme-linked immunosorbent assay (ELISA), rather than immunohistochemical techniques.
Materials and methods
Surgical specimens. Surgical specimens were obtained from 125 patients (29 males and 96 females) who underwent surgery for nodular thyroid disease. The mean age of the patients was 52 years (range 11-83 years). The study was per- Isolation of cytosolic fraction. The supernatant obtained after the separation of the nuclei from the homogenate of thyroid pathological specimens was used for cytosolic fraction isolation (21) . This supernatant was subjected to centrifugation in order to remove the residues of nuclei and the mitochondrial and microsomal fractions. The supernatant obtained after centrifugation at 100,000 x g for 1 h was considered the cytosolic fraction.
Enzyme-linked immunosorbent assay.
For semi-quantitative analysis of CK19 expression in the cytosol, the ELISA was used. Samples of cytosolic fraction to be assayed for the presence of CK19 were diluted to a final concentration of 2.5 μg/ml in 0.1 M carbonate buffer, pH 9.8. The diluted samples (100 μl) were added to the wells of 96-well microtiter polystyrene plates (Bio-Rad, Hercules, CA, USA). The attachment of proteins to the wells was effected by overnight incubation at 4˚C, following which the plates were washed three times with Tris-buffered saline containing 0.05% Tween-20 (TTBS). The non-specific binding sites were blocked by the addition to each well of 200 μl 2% BSA in TTBS buffer, followed by incubation for 1 h at room temperature. Microtiter plates were again washed three times with TTBS and incubated for 1 h at room temperature with 100 μl per well of mouse monoclonal anti-CK19 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:1000 in TTBS. After the plates were washed three times with TTBS buffer, goat anti-mouse antibodies conjugated with horseradish peroxidase (100 μl per well) (Santa Cruz Biotechnology) were added (1:5000 dilution of antibodies). The plates were incubated for 1 h at room temperature and washed with three changes of TTBS. (23) . The blots were treated for 2 h with blocking reagent (0.5% casein in TBS) then incubated for 1 h with mouse monoclonal anti-CK19 antibody in a 1:1000 dilution. After being washed three times with TBS, the membranes were incubated for 1 h with goat anti-mouse antibodies conjugated with horseradish peroxidase, added in a 1:5000 dilution. The membranes were again washed three times with TBS and the color reaction was carried out by incubating the membranes with chromogenic substrate for peroxidase, 4-chloro-1-naphtol and H 2 O 2 .
Measurement of protein concentration. Protein content was assayed using bovine serum albumin as a standard by the method of Lowry et al (24) .
Statistical analysis. Statistical analysis was performed using the computer program Statistica version 5.5 (StatSoft Inc.). The groups were compared using the Mann-Whitney rank sum test. A P-value <0.05 was considered statistically significant.
Results
For semi-quantitative analysis of CK19 expression in the cytosolic fraction of thyroid lesions, the ELISA was used. with the ELISA revealed a significant difference between the CK19 expression of papillary carcinomas and benign lesions, i.e. nodular goiters and follicular adenomas. The majority of samples of papillary carcinoma indicated stronger reactivity with the CK19 antibody than did non-neoplastic lesions and adenomas (P<0.001). There were no statistically significant differences between adenomas and non-neoplastic lesions (P>0.05). The low number of follicular carcinomas and anaplastic carcinomas precluded statistical analysis, but it appears that in both types of cancer CK19 expression is lower than in papillary carcinoma and higher than in non-neoplastic lesions and adenomas. For Western blot analysis, 50 μg of homogenate and cytosolic proteins were separated by 8% SDS-PAGE and electrophoretically transferred onto an Immobilon-P membrane. Equal protein loading was confirmed by Ponceau S staining of the transferred proteins (data not shown). Immunoblotting as well as the ELISA were performed using anti-CK19 monoclonal antibody and horseradish peroxidaseconjugated secondary antibody, and detection was by color reaction with 4-chloro-1 naphtol as a substrate for peroxidase. The representative results of CK19 expression in the different thyroid lesions obtained after Western blotting are shown in Fig. 2 and summarized in Table I . Of the 28 analyzed nodular goiter specimens, CK19 was positive in only 3 cases (11%). Six of the 27 (22%) follicular adenoma specimens showed reactivity with the CK19 antibody. Only in one case of nodular goiter and one case of follicular adenoma was the intensity of the band corresponding to CK19 extremely high. Of the 53 papillary carcinoma cases, CK19 was positive in 66% (35/53). In 15 (28%) cases expression was extremely high, and in 7 (13%) it was moderate. One of the 4 (25%) cases of follicular and anaplastic carcinoma was CK19-positive.
The additional band observed below the one corresponding to CK19 may represent the product of its degradation ( Fig. 2A) . It has been reported that, upon its release from tumor cells, CK fragments can be detected in a number of body fluids, including blood (25) .
Discussion
The prognosis and management of thyroid nodular diseases depend on their diagnosis. Several markers of malignancy have been investigated, but all present some advantages and some limitations. The utility of CK19 in the diagnosis of thyroid carcinomas is controversial. To date, studies concerning the expression of CK19 in thyroid lesions have been limited to immunohistochemistry and immunocytochemistry, and published results vary (Table II) . Several authors have reported 70-100% positive cases of papillary carcinomas. There are wide discrepancies between the results concerning CK19 expression in adenomas and in follicular carcinomas (5-100% and 21-100%, respectively). The reasons for the discrepancies in the results concerning CK19 expression in thyroid lesions as reported by different authors are unclear, but may partially be due to the subjectivity involved in assessing positive expression. Sahoo et al (18) found CK19 expression in a high percentage of non-neoplastic lesions and benign tumors, but considered the cases positive even when CK19 was expressed in <5% of tumor cells. Other researchers considered CK19 expressed when at least 10% of cells were positive (26) . Barroeta et al (28) , who studied the value of several immunohistochemical markers in the diagnosis of follicular-derived lesions of the thyroid, scored staining as positive when >25% of the lesional cells showed positive immunostaining. CK19 was positive in 70% of malignant thyroid lesions and in 34% of benign ones. 
----------------------------------------------------------------------------------------------------Histologic diagnosis
No. of cases CK19 negative CK19 positive ----------------------------------------------------------------------------------------------------- a 1, weakly; 2, moderately; 3, strongly positive. The inconsistent results concerning the immunoreactivity of CK19 in thyroid lesions may also be explained by variations in fixation and embedding methods. Tissue staining is dependent on the handling and processing of the tissue prior to staining, and the interpretation of the results is also crucial. In some cases, thyroid tumor cells show only borderline positive reactions, whereas in others the reaction is diffuse. In addition, some portions of tissue present clusters of stained cells while other portions do not. At times, the marker is restricted to only a few scattered cells.
It has been suggested that the examination of cytologic specimens is more useful than that of histologic specimens, as immunocytochemical study can be carried out before the operation (14, 15) . Hirokawa et al (15) , during immunocytochemical analysis of thyroid lesion smears, found that staining patterns differed between papillary carcinomas, adomatous goiters and follicular neoplasms. While the staining pattern of papillary carcinoma was mainly pancytoplasmic, in adomatous goiters and follicular neoplasms the immunoreactivity of the cell membrane tended to be stronger than that of the intracytoplasm.
In the present study, the utility of CK19 in the diagnosis of thyroid lesions was evaluated using methods other than immunohistochemisty. Taking into account the fact that CK19 has primarily cytoplasmic distribution in papillary carcinomas, we decided to compare CK19 expression in the cytosolic fraction obtained from different types of thyroid lesions. During cytosolic fraction isolation, all membrane fractions are removed; therefore, CK19 in the cytosolic fractions of goiters and adenomas should be less abundant. The results obtained with the ELISA show much higher CK19 expression in papillary carcinomas than in nodular goiters and adenomas. In 17 of 48 (35%) cases of papillary carcinomas, absorbance was extremely high in comparison with the other lesions. However, the differences between papillary carcinomas and the other carcinomas remain unclear. The low number of cases of follicular and anaplastic carcinomas prevented us from reaching a conclusion concerning the utility of CK19 in distinguishing between papillary and other types of carcinoma.
Western blot analysis revealed the presence of CK19 in the cytosol of 66% of papillary carcinoma cases, and in only 11 and 22% of nodular goiter and follicular adenoma cases, respectively. It is important to note that the band corresponding to CK19 was usually more intense in cases of papillary carcinoma than in other thyroid lesions. The much higher percentage of positive reactions in the case of papillary carcinomas confirms the results obtained from immunohistochemistry studies, which suggest the utility of CK19 expression analysis in papillary carcinoma diagnosis. However, in our experimental conditions, >30% of cases of papillary carcinoma did not show the presence of CK19.
In conclusion, these results confirm that the evaluation of CK19 may be helpful in the diagnosis of papillary carcinoma. In accordance with the results of previous immunohistochemical studies, our data reveal a marked upregulation of CK19 expression in papillary carcinomas, which is in particular contrast with the low levels of CK19 expression observed in follicular adenomas and nodular goiters. At least one third of papillary carcinomas showed extremely high expression of CK19. However, we must emphasize that CK19 is not a conclusive marker for papillary carcinoma, and cannot by itself be used to establish a diagnosis. Table II . Expression of cytokeratin 19 in thyroid lesions analyzed by immunohistochemistry (summary of main published results). ---------------------------------------------------------------------------------------------------- 
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